Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on NOVARTIS
06/01 NOVARTIS : isnt messing around with CAR-T, and it has a promising next-gen thera..
06/01 NOVARTIS : Spectacular early results for Novartis CAR-T combined with Imbruvica
05/31 NOVARTIS : Progress reported in global fight against diarrheal disease cryptospo..
05/31 Novartis CEO sees no need for big takeover
05/31 NOVARTIS : Sandoz proposed biosimilars adalimumab and infliximab accepted for re..
05/31 NOVARTIS : At the Meet Novartis Management investor event, Novartis highlights f..
05/30 NOVARTIS : next generation CAR-T cell therapy CTL119 combined with ibrutinib sho..
05/30 THE UPS AND DOWNS OF NOVARTIS AG (AD : NVS)’s Latest Approval
05/26 NOVARTIS : receives FDA approval for expanded use of Zykadia® in first-line ALK-..
05/26 NOVARTIS : CONTRACT AWARD - Rivastigmine 24 hr Patch
05/26 NOVARTIS : MILITARY $13.85 Million Federal Contract Awarded to Sandoz
05/25 NOVARTIS : data at ASCO, ICML and EHA meetings demonstrate meaningful advancemen..
05/24 WEAK Q4 : Novartis India plunges over 4%
05/24 NOVARTIS INDIA : posts Q4 net at Rs 2.91 crore
05/23 NOVARTIS : ' new analyses reinforce the potential of Ultibro® Breezhaler® for CO..
05/19 NOVARTIS : receives positive CHMP opinion for first-line use of Zykadia® in ALK-..
05/18 NOVARTIS : receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack ..
05/18 NOVARTIS : Researchers Submit Patent Application, "Methods of Treating Anorexia"..
05/18 DURECT : and Sandoz have Signed a $293 Million Development and Commercialization..
05/18 NOVARTIS : to cut around 500 jobs in Switzerland, add 350
05/18 NOVARTIS : data at ASCO, ICML and EHA meetings demonstrate meaningful advancemen..
05/17 NOVARTIS : Combine Solicitation - Alcon Phaco Cartridges
05/17 NOVARTIS : Foundation and partners launch initiative to tackle hypertension and ..
05/17 NOVARTIS : Higginbotham, Alcon nominated for Texas Enterprise Zone projects by F..
05/16 NOVARTIS AG : Today's Research Reports on Stocks to Watch: GlaxoSmithKline and N..
05/13 ZIONS BANCORP : Iab Financial Bank Cuts Stake in Novartis Ag
05/11 NOVARTIS : Patent Issued for Process for Manufacturing 5-(2,6-Di-4-Morpholinyl-4..
05/11 NOVARTIS : receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acu..
05/11 NOVARTIS : "Compounds and Compositions as Kinase Inhibitors" in Patent Applicati..
05/11 NOVARTIS : Patent Issued for Polymerizable Polysiloxanes with Hydrophilic Substi..
05/11 NOVARTIS : Researchers Submit Patent Application, "3'-[(2z)-[1-(3,4-Dimethylphen..
05/11 NOVARTIS : celebrates 21st annual Community Partnership Day with over 24,500 ass..
05/10 TORRENT PHARMACEUTICALS : Pharma acquires two Novartis brands
05/09 Torrent completes regestrone acquisition
05/09 NOVARTIS : Torrent Pharma acquires two women healthcare brands from Novartis
05/09 NOVARTIS : Torrent pharma acquires two women health care brands
05/08 NETWORKNEWSBREAKS – DURECT COR : DRRX) Shares Soar on $293M Development, M..
05/08 DURECT CORPORATION (NASDAQ : DRRX) Files An 8-K Entry into a Material Definitive..
05/05 Novartis sees local drug market taking off as demand surges
05/04 NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
05/04 Swiss pharma group Novartis AG organizes health lectures in Xinjiang
05/04 CONATUS PHARMACEUTICALS INC. (NASDAQ : CNAT) Files An 8-K Other Events
05/04 NOVARTIS : Sandoz Proposed Biosimilars Recommended for Approval in Europe
05/04 NOVARTIS : exercises exclusive option agreement with Conatus for the treatment o..
05/04 NOVARTIS : exercises exclusive option agreement with Conatus for the treatment o..
05/02 NOVARTIS : Tort/Negligence - Fraud – Off-Label Drug Promotion – Gene..
05/01 NOVARTIS : receives FDA approval for Rydapt in newly diagnosed FLT3-mutated acut..
04/29 NOVARTIS : Korea fined W55b, faces insurance coverage ban over bribery
04/28 NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
04/28 NOVARTIS : receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acu..
04/28 NOVARTIS : to globally co-commercialise Amgens migraine drug
04/28 NOVARTIS : FDA approves 1st targeted drug for certain leukemia patients
04/27 NOVARTIS : Patent Issued for Formulation Comprising Benzothiazolone Compound (US..
04/27 NOVARTIS : Allergan Expands Leading Research & Development NASH Program with Nov..
04/27 NOVARTIS : Patent Issued for Process for Manufacturing an Ophthalmic Lens (USPTO..
04/27 NOVARTIS : Patent Issued for Process for Preparing Intermediates Useful in the M..
04/27 NOVARTIS : Patent Issued for Method for Making Contact Lenses (USPTO 9623614)
04/27 NOVARTIS : NIH study in NEJM shows Novartis drug eltrombopag as first-line thera..
04/27 NOVARTIS : Patent Issued for Pharmaceutical Composition (USPTO 9622975)
04/27 NOVARTIS : CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designati..
04/27 NOVARTIS : Patent Application Titled "Use of Serelaxin to Reduce Gdf-15" Publish..
04/27 NOVARTIS : to globally co-commercialise Amgen's migraine drug
04/27 NOVARTIS : and Amgen expand global collaboration to commercialise AMG 334
04/26 NOVARTIS : Justices hear dispute over lower-cost biotech drugs sales
04/26 MEREO BIOPHARMA : Issues Shares To Novartis For Loan Note Conversion (ALLISS)
04/26 NOVARTIS : $32,030 Federal Contract Awarded to Alcon Laboratories
04/26 NOVARTIS : Alcon announces EU launch of CyPass® Micro-Stent, a micro invasive gl..
04/25 NOVARTIS AG (NYSE : NVS) reported earnings of $1.13 per share beating Walls Stre..
04/25 NOVARTIS : expands global collaboration with Amgen to commercialize first-in-cla..
04/25DJELI LILLY AND : Working to Cut Costs
04/25 NOVARTIS : Sandoz proposed biosimilars recommended for EU approval
04/25 NOVARTIS : beats 1Q profit forecasts
04/25DJNOVARTIS : Profit Dented by Investment in New Drugs -- Update
04/25DJNOVARTIS : 1Q Net Income Down 17%, Hurt by Drug Failure
04/25 NOVARTIS : delivered sales growth across all divisions (cc1) as growth drivers, ..
Prev.1   2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ($)
Sales 2017 48 383 M
EBIT 2017 11 853 M
Net income 2017 7 439 M
Debt 2017 15 454 M
Yield 2017 3,28%
P/E ratio 2017 25,91
P/E ratio 2018 22,82
EV / Sales 2017 4,93x
EV / Sales 2018 4,71x
Capitalization 222 848 M
More Financials
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 82,4 $
Spread / Average Target -4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS12.55%222 848
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
SANOFI13.95%125 371
More Results